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Abstract
Aim: To elucidate the mechanisms underlying homocysteine (Hcy)-induced
chemokine production.  Methods: Human whole blood was pretreated with in-
hibitors of calmodulin (CaM), protein kinase C (PKC), protein tyrosine kinase
(PTK),  mitogen-activated protein kinase (MAPK), and NF-κB  and activators of
PPARγ for 60 min followed by incubation with Hcy 100 µmol/L for 32 h. The
levels of mitogen chemokine protein (MCP)-1 and interleukin-8 (IL-8) were de-
termined by enzyme-linked immunosorbant assay (ELISA). Results: Inhibitors
of PKC (calphostin C, 50-500 nmol/L and RO-31-8220, 10–100 nmol/L), CaM
(W7, 28–280 µmol/L), ERK1/2 MAPK (PD 98059, 2–20 µmol/L), p38 MAPK
(SB 203580, 0.6–6 µmol/L), JNK MAPK (curcumin, 2–10 µmol/L), and NF-κB
(PDTC, 10-100 nmol/L) markedly reduced Hcy 100 µmol/L-induced production
of MCP-1 and IL-8 in human cultured whole blood, but the inhibitors of PTK
(genistein, 2.6–26 µmol/L and tyrphostin, 0.5-5 µmol/L) had no obvious effect on
MCP-1 and IL-8 production. PPARγ activators (ciglitazone 30 µmol/L and
troglitazone 10 µmol/L) depressed the Hcy-induced MCP-1 production but not
IL-8 production in the cultured whole blood.  Conclusion:  Hcy-induced MCP-1
and IL-8 production is mediated by activated signaling pathways such as PKC,
CaM, MAPK, and NF-κB. Our results not only provide clues for the signal trans-
duction pathways mediating Hcy-induced chemokine production, but also offer a
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Introduction
Hyperhomocysteinemia is an independent risk factor for
atherosclerosis and venous thrombosis.  We have found that
an increased homocysteine (Hcy) levels in cultured whole
blood can promote the production of monocyte chemo-
attractant protein-1 (MCP-1) and interleukin-8 (IL-8)[1].  As po-
tent proatherosclerotic factors, MCP-1 and IL-8 are consid-
ered to be vital contributing factors in the pathogenesis of
atherosclerosis and venous thrombosis[2–6].  Therefore, increased
MCP-1 and IL-8 levels in plasma may be an important mecha-
nism by which hyperhomocysteinemia promotes the progres-
sion of atherosclerosis.
In addition, the relationship between hyperhomocy-
steinemia and the cardiovascular disease and thrombosis has
been well established.  Recent clinical investigations have
found that hyperhomocysteinemia is also associated with
many different diseases such as inflammation, autoimmune
diseases, and cognitive diseases[7–13].  These new findings
imply that Hcy may also mediate the development of these
medical conditions by presently-unknown mechanism(s).
Previous studies have found that the signaling pathways
involving protein kinase C (PKC), protein tyrosine kinase
(PTK), or mitogen-activated protein kinase (MAPK) play a
vital role in the mediation of MCP-1 and IL-8 production in
response to other stimuli[14–18].  Thus, these signaling path-
ways are examined in the present study to explore which
86
 Acta Pharmacologica Sinica ISSN 1671-4083Zeng XK et al
signaling pathways are involved in the Hcy-induced produc-
tion of MCP-1 and IL-8.  Our results presented here demon-
strate that inhibitors of PKC, CaM, MAPK and NF-κB in-
hibit Hcy-induced MCP-1 and IL-8 production in cultured
whole blood.  Our results suggest that activation of these
signaling pathways is involved in Hcy-induced chemokine
production.  Considering the fact that abnormally activated
PKC, CaM, MAPK, and NF-κB play important roles in the
initiation and progression of autoimmune and cognitive dis-
eases[19-22], our study provides useful clues as to why Hcy
may be involved in these diseases.
Materials  and  methods
Human whole blood culture  The investigation conforms
to the principles outlined in the Declaration of Helsinki.  The
human whole blood cultures were slightly modified from our
previous studies[23,24].  Briefly, blood from healthy donors
was drawn into heparinized syringes.  Whole blood was then
placed on a rotator and incubated at 37 ºC in an atmosphere
containing 5% CO2.  Cell viability was evaluated by Trypan
blue exclusion.  Only cell preparations with a 95% or greater
viability were used.
Measurement of MCP-1 and IL-8 protein secretion
Human whole blood was treated with Hcy for indicated times
and/or preincubated for 60 min with genistein, tyrphostin,
calphostin C, RO-31-8220, W7, SB 203580, PD 98059, and
curcumin or other pharmacological reagents.  The plasma
was harvested and transferred to other polypropylene tubes
and stored at -30 ºC for not more than 1 week before mea-
surement of chemokines MCP-1 and IL-8 protein concen-
trations in the plasma, which were determined by ELISA
(R&D Systems Inc, Minneapolis, MN).
Chemicals  L-homocysteine (L–Hcy), L-cysteine,
L-methione, genistein, tyrphostin, and pyrrolidine dithiocar-
bamate (PDTC) were purchased from Sigma Co (St Louis,
MO).  Calphostin C, RO-31-8220, W7, SB 203580, PD
98059, and curcumin were purchased from Calbiochem Co
(La Jolla, CA).  2 -́7 -́DCFH-DA was obtained from Molecu-
lar Probes (Eugene, OR).  RPMI-1640 was purchased from
Gibco Laboratories (Grand Island, NY).  Other chemicals
were purchased from the Chinese Chemical Co (Beijing,
China).
Statistical analysis  Results are expressed as mean±SEM.
The number of samples used for each group is presented in
the figure legends.  The data were analyzed using one-way
ANOVA and further analyzed using the Student-Newmen-
Keuls test for multiple comparisons within treatment groups
or the t-test (unpaired test with Welch’s correction) for com-
parison between two groups with non-normal distribution.
P<0.05 was considered a significant difference between treat-
ment groups. 
Results
Effect of L-methionine and L-cysteine on MCP-1 and
IL-8 production from human whole blood   To understand
the role of thiol residues in Hcy-induced chemokine
production, human whole blood was treated with sulfur-
containing amino acids, L-methionine and L-cysteine 100
µmol/L for 32 h.  Neither L-methionine nor L-cysteine el-
evated the production of MCP-1 and IL-8 in cultured human
whole blood (Figure 1A, 1B).  These data suggest that the
thiol residues do not play an important role in the Hcy
mechanisms.
PKC, PTK, and CaM in Hcy-induced secretion of
MCP-1 and IL-8  A substantial body of evidence indicates
that activation of PKC, CaM, PTK, MAPK, and NF-κB may
Figure 1.  Effects of L-methionine (Met) and L-cysteine (Cys) on the secretion of MCP-1 and IL-8 in cultured human whole blood.  The levels of
MCP-1 (A) and IL-8 (B) in cultured human whole blood were measured by ELISA assays after incubation with  Met or Cys 100 µmol/L for 32 h.  n=6.
Mean±SEM.  bP<0.05 vs corresponding untreated control (con) group.
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be involved in chemokine production.  Therefore, we hy-
pothesize that such signaling pathways might contribute to
Hcy-induced chemokine expression and secretion in cultured
whole blood.  Human whole blood was pretreated with in-
hibitors of CaM (W7, 28–280 µmol/L), PKC (calphostin C,
50–500 nmol/L and RO-31-8220, 10–100 nmol/L), PTK
(genistein, 2.6-26 µmol/L and tyrphostin, 0.5-5 µmol/L).
CaM and PKC inhibitors significantly inhibited Hcy-induced
MCP-1 and IL-8 production in cultured human whole blood
(Figure 2). However, the inhibitors of PTK had no obvious
effect on chemokine production (Figure 3).  These data show
that the activated signaling pathways of PKC and CaM are
involved in the Hcy-induced production of MCP-1 and IL-8
in cultured whole blood.
MAPK and NF-κB in Hcy-induced MCP-1 and IL-8
production To further study the role of the downstream sig-
naling molecules of PKC and CaM, such as MAPK and NF-
κB, in the Hcy-induced MCP-1 and IL-8 production, the in-
hibitors of ERK1/2 MAPK (PD 98059, 2–20 µmol/L), p38
MAPK (SB 203580, 0.6-6 µmol/L), JNK MAPK (curcumin,
2–10 µmol/L), and NF-κB (PDTC, 10–100 nmol/L) were
added to cultured whole blood for 60 min, respectively.  This
was followed by stimulation with Hcy 100 µmol/L for 32 h.
As shown in Figure 4, MAPK (p38, ERK1/2, and JNK) in-
hibitors significantly inhibited Hcy-induced MCP-1 and
IL-8 production in cultured human whole blood.  In addition,
the NF-κB inhibitor PDTC also prevented Hcy-induced
Figure 2.  Effects of CaM and PKC inhibitors on Hcy-induced MCP-1
(A) and IL-8 (B) production in cultured human whole blood.  Cultured
whole blood was pretreated with the CaM inhibitor W7 or the PKC in-
hibitors calphostin C (Cal) and RO 31-8220 (RO) for 60 min and then
stimulated by Hcy 100 µmol/L for 32 h.  n=4.  Mean±SEM.  bP<0.05 vs
the Hcy only group.
Figure 3.  Effects of PTK blockers on Hcy-induced MCP-1 (A) and IL-8
(B) in cultured human whole blood.  Cultured whole blood was pretreated
with the the PKC inhibitors tyrphostin and genistein for 60 min and then
stimulated by Hcy 100 µmol/L for 32 h.  n=4.  Mean±SEM.  bP<0.05 vs
the Hcy-treated only group.
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MCP-1 and IL-8 production in the cultured whole blood
(Figure 5A, 5B).  These data show that the activation path-
ways of MAPK and NF-κB are involved in the regulation of
the Hcy-induced secretion of MCP-1 and IL-8.  In the range
of inhibitors examined, Hcy (10–1000 µmol/L) did not sig-
nificantly increase LDH release as compared with the con-
trol (data not shown), indicating that Hcy plus the inhibitors
did not have an obvious toxic effect on human whole blood.
Influence of PPARγ activators on Hcy-induced MCP-
1 and IL-8 production  Cultured whole blood was pretreated
with the activators of PPARγ (ciglitazone 30 µmol/L and
troglitazone 10 µmol/L) for 60 min, respectively.  It is fol-
lowed by stimulation with Hcy 100 µmol/L for 32 h.  The
data showed that PPARγ activators depressed the Hcy-in-
duced MCP-1 production but not IL-8 production in the cul-
tured whole blood (Figure 6A, 6B).
Discussion
Our previous work showed that an increased Hcy level
promoted the production of MCP-1 and IL-8 in cultured
whole blood.  This suggests that hyperhomocysteinemia may
upregulate MCP-1 and IL-8 levels in plasma and conse-
quently promote the initiation and progression of atheroscle-
rosis and venous thrombosis.  Our present study demonstrated
that  activated signaling pathways such as PKC, CaM,
Figure 4.  Effects of MAPK blockers on Hcy-induced MCP-1 (A) and
IL-8 (B) in cultured human whole blood.  Cultured whole blood was pre-
treated with the p38 MAPK inhibitor SB 203580 (SB), or the ERK1/2
inhibitor PD 98059 (PD) or the JNK inhibitor curcumin (CU) for 60 min
and then stimulated by Hcy 100 µmol/L for 32 h.  n=3.  Mean±SEM.
bP<0.05 vs the Hcy-treated only group.
Figure 5.  Effects of NF-κB on Hcy-induced MCP-1 (A) and IL-8 (B) in
cultured human whole blood.  Cultured whole blood was pretreated with
the NF-κB inhibitor, PDTC (10–100 nmol/L) for 60 min and then stimu-
lated with Hcy 100 µmol/L for 32 h.  n=3 independent experiments.  Mean±
SEM.  bP<0.05 vs the Hcy-treated only group.
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MAPK, and NF-κB were involved in the mediation of Hcy-
induced MCP-1 and IL-8 production.  These data indicate
that Hcy promotes MCP-1 and IL-8 production in cultured
whole blood by activating these signaling pathways.  It fur-
ther suggested that abnormally activated signaling pathways,
which were caused by Hcy, might play roles as vital mecha-
nisms underlying Hcy-mediated inflammatory, autoimmune,
and cognitive diseases.
PKC is thought to play an important role in Hcy-induced
MCP-1 production in cultured vascular smooth muscle cell
lines, but not in endothelial lines[25,26].  Our present results shows
that the activation of PKC is necessary for both IL-8 and
MCP-1 production induced by Hcy, since calphostin C and
RO31-8220, inhibitors of PKC, significantly reduced MCP-
Figure 6.  Effects of PPARγ agonists on Hcy-induced MCP-1 (A) and IL-
8 (B) in cultured human whole blood.  Cultured whole blood was pre-
treated with PPARγ activators, ciglitazone (30 µmol/L) and troglitazone
(10 µmol/L) for 60 min and then stimulated by Hcy 100 µmol/L for 32 h,
respectively.  n=3 independent experiments.  Mean±SEM.  bP<0.05 vs
the Hcy-treated only group.
1 and IL-8 synthesis.  No inhibitory effect was observed with
the PTK inhibitors, genistein and tyrphostin, which indicates
that protein tyrosine kinase might not be involved in Hcy-
mediated MCP-1 and IL-8 synthesis.  Previous studies have
also shown that calcium/CaM plays an important role in the
mediation of IL-8 production in several other cell systems[27,28].
To test whether calcium/CaM is involved in the Hcy-induced
chemokine synthesis, we used W7, a potent inhibitor of CaM,
to study its influence on Hcy-induced chemokine synthesis
in cultured whole blood.  Our data demonstrated that W7
significantly decreased both MCP-1 and IL-8 production.
Taken together, these results reveal that both activated PKC
and CaM are involved in Hcy-induced MCP-1 and IL-8 pro-
duction in cultured whole blood.  PTK, however, had no
significant effect on Hcy action.
MAPKs represent a family of eukaryotic protein kinases
involved in various cellular processes.  Three parallel cas-
cades are now commonly described, each of which is named
after its end-moiety: p38, the extracellular signal regulated
protein kinases (ERK), and stress activated protein kinase/c-
Jun N-terminal kinases (JNK)[29].  As the upstream signaling
molecules of MAPK, the activated PKC and CaM may me-
diate the activation of MAPK, such as MEK, p38MAPK,
and JNK.  For example, as the intermediate signaling path-
way molecules, MAPK is indispensable in the PKC-medi-
ated signaling transduction system[30,31].  Thus, we investi-
gated specific downstream signaling molecules that could
be potentially important as the targets of activated PKC and
CaM.  We demonstrated that PD98059, SB 203580, and
curcumin, the selective inhibitors of MEK1, p38 MAPK, and
JNK respectively, significantly decreased IL-8 and MCP-1
production.  This data is consistent with other reports that
MAPK is required for IL-8 and MCP-1 production in sev-
eral other cell systems in response to various stimuli[30].
NF-κB is an important transcription factor in the initia-
tion of cell growth and secretion.  Consistent with its role as
a primer in synthesis, NF-κB binds to the IκB site of various
gene promoter regions[32].  Our data demonstrate that Hcy-
induced chemokine production is almost competently
blocked by PDTC, a specific inhibitor of NF-κB.  These
results agree with those obtained in other studies[33], sug-
gesting that NF-κB has a role in the regulation of IL-8 and
MCP-1 production.
Another interesting finding is that PPAR-γ activation can
lead to a decrease in Hcy-induced MCP-1 production in cul-
tured whole blood.  PPAR-γ is a ligand-activated transcrip-
tion factor belonging to the nuclear receptor family.  PPAR-
γ is expressed in differentiated human mono/macrophages
and functions as a regulator of cellular proliferation, differen-
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tiation, and apoptosis[34].  Although PPAR-γ seems to be ab-
sent from isolated monocytes, PPAR-γ can regulate mono/
macrophage physiology[34,35].  Furthermore, Jiang et al[36]
reported that incubation of human monocytes with the natu-
ral PPAR-γ ligand, or with synthetic agonists, inhibited the
production of proinflammtory cytokines.  Other studies
showed that PPAR-γ inhibited the transcriptional activity of
genes by interfering with transcription factors such as
NF-κB[37].  Our data showed that Hcy-mediated MCP-1 and
IL-8 production was NF-κB-dependent, thereby the influ-
ence of activated PPAR-γ in the Hcy-induced chemokine pro-
duction was detected.  The activators of PPAR-γ significantly
depressed the production of MCP-1 but not IL-8.  It sug-
gests that this is an important pathway for attenuating the
damage of Hcy or other inflammatory mediators.  The dif-
ferent inhibitory effects on MCP-1 and IL-8 production im-
ply that the regulation of Hcy-induced MCP-1 and IL-8 pro-
duction is slightly different, at least in the cultured whole
blood system.
Our previous studies and other work showed that Hcy
potentiated lymphocyte proliferation. Also the thiol-contain-
ing compounds, such as cysteine had similar effects on lym-
phocyte proliferation[17,18].  The other compounds without
thiol have no such effect.  This suggests that thiol residue
plays a key role in Hcy-induced lymphocyte proliferation.
Our current studies found that thiol-containing compounds,
such as cysteine and methionine, failed to promote MCP-1
and IL-8 production in the cultured whole blood.  These re-
sults are consistent with previous work[38], suggesting that
thiol may play a less important role in Hcy-induced chemo-
kine production.  Thus, there is the possibility that different
sites of Hcy are responsible for different Hcy action.
Our current research has three implications; first, Hcy-
induced MCP-1 and IL-8 production is mediated by acti-
vated signaling pathways such as PKC, CaM, MAPK, and
NF-κB.  Second, although the exact mechanism is unclear,
current studies suggest that Hcy is able to activate the PKC,
CaM, MAPK, and NF-κB signaling pathways.  When we
take the consideration that these activated signaling path-
ways are involved in many pathological and physiological
functions, especially, in the initiation and progression of many
immune and cognitive diseases, our findings shed light on a
possible answer to why hyperhomocysteinemia has been
found to be linked with not only cardiovascular diseases,
but also so many inflammatory, autoimmune and cognitive
diseases.  Finally, activated PPAR-γ inhibited Hcy-induced
MCP-1 production.  This study provides a novel approach
to partly attenuate the proatherogenic effect of hyperhomo-
cysteinemia.
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